Background
Phase III RCT (GHSG HD4). 227 patients with stage IA–IIA early favorable Hodgkin lymphoma. Compared combined modality therapy (CMT) vs extended-field radiotherapy (EFRT) alone. Trial addressed whether adding brief chemotherapy to RT improves disease control over RT alone. Median follow-up 7 years.
Interventions and follow up
Arm A: 2 cycles COPP/ABVD + involved-field RT (IFRT) 30 Gy (n=114)
Arm B: Extended-field RT (EFRT) 30 Gy alone — mantle ± para-aortic-splenic fields (n=113)
Primary endpoint: Freedom from treatment failure (FFTF)
mFollow up: 7 year
Arm B: Extended-field RT (EFRT) 30 Gy alone — mantle ± para-aortic-splenic fields (n=113)
Primary endpoint: Freedom from treatment failure (FFTF)
mFollow up: 7 year
Results
FFTF at 7 years: 78% (CMT) vs 67% (EFRT alone), P=.003
OS at 7 years: 96% (CMT) vs 92% (EFRT alone) — not statistically significant
Relapse rate: Significantly lower with CMT (P=.003)
OS at 7 years: 96% (CMT) vs 92% (EFRT alone) — not statistically significant
Relapse rate: Significantly lower with CMT (P=.003)
Adverse events
Main adverse events: Combined modality therapy added chemotherapy-related toxicity (nausea, hematologic); RT alone had higher field-related toxicity. Second malignancy rates and late cardiac/pulmonary toxicity reported with extended follow-up in subsequent analyses.
Conclusions
Combined modality therapy with 2 cycles COPP/ABVD + IFRT significantly improved freedom from treatment failure compared with extended-field RT alone for early favorable Hodgkin lymphoma. These results contributed to the shift away from radiation-alone strategies toward combined modality approaches.
Key Limitations
Key Limitations: Small sample size (n=227) may be underpowered for OS. COPP/ABVD is not the modern standard (ABVD has supplanted it); results may not directly apply to ABVD-based CMT. Extended-field RT alone is no longer standard and has been replaced by IFRT and involved-site RT (ISRT). Long-term second malignancy risk of RT not fully captured.
Clinical Context
HD4 was one of the early trials establishing CMT superiority over RT alone for early HL in the GHSG series. Subsequent GHSG trials (HD7, HD10) refined the number of ABVD cycles and RT dose to minimize toxicity while maintaining efficacy. Current standard is 2 cycles ABVD + 20 Gy ISRT for early favorable HL (HD10 results).
References
References: Duhmke E et al, JCO 2001 (GHSG HD4)